6 February 2019

Cell line of the month - FGF21

iLite® FGF21 Responsive Reporter Gene Cell Line With Improved Sensitivity

FGF21 holds promise to become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within reach.

Fibroblast growth factor 21 (FGF21) is a hot target within the diabetes and obesity research and drug discovery. Known to function as an endocrine hormone with documented beneficial metabolic effects, FGF21 has been established as a viable, and excellent drug candidate molecule for therapeutic treatment of diabetes and cardiovascular disease associated with obesity.

The iLite® FGF21 Assay Ready Cells are genetically engineered reporter gene cells responsive to FGF21 by specific and proportional expression of Firefly Luciferase. As transmembrane protein β-Klotho has been identified as the necessary co-receptor able to permit FGF21 mediated activation of FGFRs in vitro and promote FGF21 action in vivo, the receptor chain FGFR1c in this new and improved cell line is overexpressed on the surface together with the co-factor β-Klotho which has been genetically optimized to enhance sensitivity.

FGF21 holds promise to eventually become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within the reach.

iLite® Cell-Based Assays
Valuable tools during the whole drug development continuum

iLite® cell lines can be developed for any biopharmaceutical target,  and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The iLite® technology eliminates many of the limitations of conventional cell-based assays as the cells are delivered as assay ready frozen cells, allowing cell-based assays to be carried out without the need for cell culture or the maintenance of cells continuously in the laboratory.

This allows for significant cost reductions and increases the applicability of cell-based assays to routine use as potency or neutralization assays.

For more information about our iLite® Assay Ready Cells - please click here.

The iLite® technology is used by a number pharmaceutical- and biotechnology companies for the quantification of drug potency and detection of neutralizing antibodies (NAbs).

If the currently available iLite® cell lines don´t match you needs, explore the possibility of a custom development project.